Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Sospeter B, MD
16 Juni 2021 19:26:26
Lamivudine na ujauzito
Lamivudine kwa jina jingine 2′,3′-dideoxy-3′-thiacytidine au 3TC ni dawa ya kutibu maambukizi ya virusi vya UKIMWI, kiumbile hufanana na zalcitabine. Hufanya kazi kwa kuzuia kimeng’enya cha reverse transcriptase na hivyo kuzuia uzalishaji wa DNA ya kirusi.
Hakuna madhara yaliyotokea kwa vichanga wa panya na sungura waliotumia dawa hii katika dozi zaidi ya mara 130(panya) kwa 60(sungura) ya dozi ya kawaida anayotumia binadamu. Dawa hata hivyo ilihusika kusababisha kifo kwa kijusi wa panya tumboni kwenye dozi inayotumika kwa binadamu na zaidi ya hiyo lakini haikuwa hivyo kwa sungura.
Taarifa za wanyama na binadamu zinapendekeza dawa hii kuwa kwenye kundi la hatari kidogo kusababisha madhaifu ya kiuumbaji kwa kijusi tumboni mwa mama. Kinadharia, kutumia dawa hii wakati wa upandikizaji wa yai lililochavushwa huweza kusababisha madhaifu ya upandikizaji na hivyo kutoendelea kwa ujauzito. Madhaifu ya maitoondria yanayotokea kwa watumiaji wa dawa jamii ya NRTI yanahitajika kufanyiwa tafiti zaidi. Licha ya yote, hata kama kuna mahusiano yaliyothibitishwa, faida ya matumizi ya dawa hii kuzuia madhara na kifo kutokana na UKIMWI ni kubwa zaidi kulinganisha na hatari inayoweza kujitokeza kwenye ujauzito. Endapo imependekezwa kutumika, isisitishwe kwa sababu ya ujauzito.
Dawa hii hupita na kuingia kwenye maziwa ya mama na hivyo inaweza kumpata mtoto. Hakuna taarifa katika nchi zilizoendelea kwa sababu wamama wanaotumia dawa hii huwa hawanyonyeshi, taarifa za nchi zinazoendelea hakuna hivyo tafiti zinabidi kufnayika kuangalia madhara yanayoweza kujitokeza kwa vichanga. Inaonekana kuwa dawa hii ikitumika kwa wamama wanaonyonysha, hupunguza usafilishaji wa virusi kwa watoto kwa asilimia 38.
Ushauri dhidi ya matumizi kwa mama mjamzito
Inapatana na ujauzito- faida kwa mama >>hatari kwa Kijusi-kichanga tumboni
Inapatana na ujauzito- faida kwa mama >>hatari kwa Kijusi-kichanga tumboni ina maana gani?
Kunaweza kuwa au kutokuwa na uzoefu wa matumizi ya dawa hii kwa binadamu, lakini faida ni kubwa zaidi zikitumiwa na mama kuliko madhara yanayofahamika au kutofahamika kuwa yanaweza kutokea kwa kijusi-kichanganya tumboni. Kwa mama dawa zinazidi madhara yanayofahammika. Taarifa za uzazi kwa wanyama hazina mahusiano.
Ushauri wa matumizi kwa mama anayenyonyesha
Haipatani na unyoyenyeshaji
Haipatani na unyoyenyeshaji ina maana gani?
Kunawezekana kuwa hakuna taarifa za uzoefu wa matumizi ya dawa hii kwa mama anayenyonyesha. Hata hivyo mkusanyiko wa taarifa zinaonyesha kuwa dawa huweza kuwa sumu kali kwa kichanga, au haishauriwi kunyonyesha endapo dawa itahitajika kutumika kwa mama mwenye anayehitajika kutumia dawa hii. Mama anatakiwa asinyonyeshe anapotumia dawa hii au akiwa na ugonjwa unaotakiwa kutumia dawa hii.
ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeboreshwa,
22 Aprili 2022 15:48:15
Rejea za mada hii;
1. Morris AAM, Carr A. HIV nucleoside analogues: new adverse effects on mitochondria? Lancet 1999;354:1046–7.
2. Product information. Epivir. Glaxo Wellcome, 2001.
3. Venerosi A, Valanzano A, Alleva E, Calamandrei G. Prenatal exposure to anti-HIV drugs: neurobehavioral effects of zidovudine (AZT) + lamivudine (3TC) treatment in mice. Teratology 2001;63:26–37.
4. Bloom SL, Dias KM, Bawdon RE, Gilstrap LC III. The maternal-fetal transfer of lamivudine in the ex vivo human placenta. Am J Obstet Gynecol 1997;176:291–3.
5. Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Leeuwen R, Goodwin C, Harrigan PR, Moore KHP, Stone C, Plumb R, Johnson MA. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998;178:1327–33.
6. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2009. Wilmington, NC: Registry Coordinating Center, 2009. Available at www.apregistry.com.Imechukuliwa 06.16.2021
7. McGowan JP, Crane M, Wiznia AA, Blum S. Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women. Obstet Gynecol 1999;94:641–6.
8. Bloch M, Carr A, Vasak E, Cunningham P, Smith D. The use of human immunodeficiency virus postexposure prophylaxis after successful artificial insemination. Am J Obstet Gynecol 1999;181:760–1.
9. Scott GB, Tuomala R. Combination antiretroviral therapy during pregnancy. AIDS 1998;12:2495–7.
10. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, Irion O, Kaiser L. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998;12:F241–7.
11. Grubert TA, Wintergerst U, Lutz-Friedrich R, Belohradsky BH, Rolinski B. Long-term antiretroviral combination therapy including lamivudine in HIV-1 infected women during pregnancy. AIDS 1999;13:1430–1.
12. Ristola M, Salo E, Ammala P, Suni J. Combined stavudine and lamivudine during pregnancy. AIDS 1999;13:285.
13. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, Ciraru-Vigneron N, Lacroix C, Rouzioux C, Mandelbrot L, Desguerre I, Rotig A, Mayaux MJ, Delfraissy JF. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084–9.
14. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112–5.
15. Stojanov S, Wintergerst U, Belohradsky BH. Mitochondrial and peroxisomal dysfunction following perinatal exposure to antiretroviral drugs. AIDS 2000;14:1669.
16. Watson WJ, Stevens TP, Weinberg GA. Profound anemia in a newborn infant of a mother receiving antiretroviral therapy. Pediatr Infect Dis J 1998;17:435–6.
17. Carpenter CCJ, Fischi MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1996. JAMA 1996;276;146–54.
18. Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol 1997;176:478–89.
19. Minkoff H. Human immunodeficiency virus infection in pregnancy. Obstet Gynecol 2003;101:797–810.
20. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents . Department of Health and Human Services. December 1, 2009;1–161. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Imechukuliwa 06.16.2021
21. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. May 24, 2010:1– 117. Available at http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Imechukuliwa 06.16.2021 (Table 5).
22. Mofenson LM, McIntrye JA. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 2000;355:2237–44.
23. Brown ZA, Watts DH. Antiviral therapy in pregnancy. Clin Obstet Gynecol 1990;33:276–89.
24. de Martino M, Tovo P-A, Tozzi AE, Pezzotti P, Galli L, Livadiotti S, Caselli D, Massironi E, Ruga E, Fioredda F, Plebani A, Gabiano C, Zuccotti GV. HIV-1 transmission through breast-milk: appraisal of risk according to duration of feeding. AIDS 1992;6:991–7.
25. Van de Perre P. Postnatal transmission of human immunodeficiency virus type 1: the breast feeding dilemma. Am J Obstet Gynecol 1995;173:483–7.